Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

severance costs ($7.2

million) and a significant one-time charitable contribution ($4.0

million).

(4) To reflect the tax effect of pre-tax adjustments at the applicable tax

rates and certain other tax adjustments primarily related to changes

in valuation allowances and other changes in tax assets and

liabilities.

(5) To exclude the write-off of other acquired in-process research and

development.

(6) To exclude the debt exchange expense associated with the December 2006

exchanges of $337.0 million of zero coupon convertible subordinated

notes and $100.0 million of 2% senior subordinated convertible notes.

(7) Amounts shown no longer exclude the impact of Financial Accounting

Standards Board Statement No. 123(R) "Share Based Payment" ("SFAS

123(R)"). The earnings press release issued on February 12, 2007

reflected adjustments of $3.7 million in each of Research and

development and Selling, general and administrative expenses and $2.9

million in Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(Unaudited)

Year Ended

December 31,

2007 2006

GAAP NET INCOME (LOSS) $(191,704) $144,816

Sales adjustments - (13,273)(8)

Cost of sales adjustments 90,542 (1) 90,333 (1)

Research and development adjustments 43,500 (2) 80,500 (2) (13)

Selling, general and administrative

adjustments 11,191 (3) 9,987 (3) (13)

Settlement reserve
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... will be one of the presenters at Digestive Disease ... in interventional gastroenterologyORANGEBURG, S.C., May 29 Zeus, Inc., ... it has been invited to present at Digestive Disease ... Dr. Bruce Anneaux, Ph.D. and GI Endoscopy Specialist Aubrey ...
... May 29 Dey L.P., a subsidiary of Mylan ... it has begun to market and distribute EMSAM(R) in ... monoamine oxidase inhibitor (MAOI), which was approved by the ... the treatment of major depressive disorder. EMSAM previously was ...
... have designed cells that can count and "remember" cellular events, ... activated in a specific order. , Such circuits, which mimic ... the number of times a cell divides, or to study ... biosensors that count exposures to different toxins. , The team ...
Cached Biology Technology:Zeus to Present at Digestive Disease Week in Chicago 2Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder 2MIT, BU engineer cellular circuits that count events 2MIT, BU engineer cellular circuits that count events 3
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its new ... G2 model. The G2 sets a higher standard for collecting ... capital management solution. With plug-and-play installation, touch screen interface and ... provides a robust time collection solution for the small to ...
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... University School of Medicine studies of Hispanic farmworkers in North ... had skin disease and that workers need more information about ... deadly diseases such as skin cancer. , Few studies have ... Wake Forest studies, 59 farmworkers from Nash and Johnston Counties ...
... most effective chemotherapy drugs against cancer is cisplatin because ... it also kills healthy tissue. Many scientists are creating ... treatments without side effects. One approach to analog development ... a Virginia Tech chemistry-biology research team that has been ...
... ensure complete tumor removal at breast cancer excision is ... used light waves in a newly explored region of ... and determine if the removed tissue margins were clear ... potential to eliminate the need for multiple surgeries and ...
Cached Biology News:Skin disease common among Hispanic farmworkers in North Carolina, research shows 2Light activated anticancer drug targeted to DNA using cisplatin like sub-units 2Terahertz imaging may reduce breast cancer surgeries 2
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Prepared from plasminogen by activation with immobilized human uPA...
Biology Products: